Header
 

News

In-vitro Comparative Study of different Selegiline Hydrochloride Bucco-Adhesive Polymeric Films / Part 1

Selegiline hydrochloride is a selective irreversible MAO-B inhibitor which is used in the treatment of early stage Parkinson's disease, depression and dementia. It shows low bioavailability due to a high hepatic first-pass metabolism. The present work was undertaken to formulate mucoadhesive buccal films of selegiline (Sel) to improve the related therapeutic efficacy, patient compliance and bioavailability. ...

An engineered protein can disrupt tumor-promoting 'messages' in human cells

Over a century of research has shined light on the once-murky innards of our cells, from the genes that serve as our "blueprints" to the proteins and other molecules that are our cellular taskmasters. Building on this basic knowledge, the search is underway for cellular mechanisms that could serve as gateways for new therapies. These could lead to precise treatments for disease—targeting a specific cellular function or gene with fewer unintended side effects. ...

Chugai und Galderma geben weltweite Lizenzvereinbarung für Nemolizumab (CIM331) bekannt, ein neues biologisches Arzneimittel für Hautkrankheiten

Chugai Pharmaceutical Co., Ltd. und Galderma Pharma S.A. gaben heute den Abschluss einer weltweiten Lizenzvereinbarung bekannt für „Nemolizumab“ (CIM331), dem humanisierten, monoklonalen Anti-IL-31-Rezeptor-A-Antikörper, der von Chugai entwickelt wurde und sich derzeit zur Behandlung von atopischer Dermatitis und Übelkeit bei Hämodialysepatienten in der Entwicklung befindet. ...